ICG- Liver Test Versus New Biomarkers as Prognostic Markers in Critically Ill Patients

Comparison of ICG liver testing with copeptin and SAPS II score as prognostic markers in critically ill patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Critically Ill Critical Illness Disease Attributes Pathologic Processes Pathological Conditions, Signs and Symptoms

Sex eligibility

All sexes

Study type

Observational

Primary location

Surgical ICU, University Hospital Zurich

Zurich, Switzerland

About this study

Comparison of different marker for length of stay in the ICU in critically ill patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients admitted to the ICU

Exclusion criteria

Not able to understand German

Treatment and study plan

Primary outcomes

prolonged length of stay in the ICU (pLOS) more than 3 days

Time frame: 3 days

see above

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Collaborators

Brahms AG

Registry information

Official study title

ICG- Liver Test Versus New Biomarkers as Prognostic Markers in Critically Ill

Acronym: Greenpep

Important dates

Study start: 2010
Primary completion: 2010
Study completion: 2011
First posted: May 19, 2010
Registry last updated: Apr 29, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed